Transaction DateRecipientSharesTypePriceValue
17th December 2020Richard Chen1,087Open or private sale$36.37$39,534.19
17th December 2020Aaron Tachibana2,391Open or private sale$36.37$86,960.67
20th October 2020Llp Abingworth130,486Open or private sale$27.66$3,609,242.76
19th October 2020Llp Abingworth196,423Open or private sale$27.86$5,472,344.78
16th October 2020Llp Abingworth94,218Open or private sale$26.68$2,513,736.24
15th October 2020Llp Abingworth3,700Open or private sale$26.32$97,384.00
14th October 2020Llp Abingworth81,925Open or private sale$27.08$2,218,529.00
13th October 2020Llp Abingworth86,819Open or private sale$28.43$2,468,264.17
12th October 2020Llp Abingworth115,541Open or private sale$29.09$3,361,087.69
1st October 2020Richard Chen37,452Exercise of derivative$0.44$16,478.88
Personalis logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West and Russ B. Altman in 2011.

Ticker: PSNL
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1527753
Employees: 182
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags